PLRZ Polyrizon Ltd.
Price Chart
Executive Summary
Polyrizon announced that the European Patent Office has completed technical preparations for publication of its European patent application covering its Trap & Target mucoadhesive polymer technology for nasal drug delivery. This is a routine IP milestone for a development-stage company with no revenue, and the patent remains subject to examination and grant. The filing provides no financial data, no partnership, and no near-term commercialization catalyst.
Actionable Insight
This is a routine IP milestone with no near-term revenue or partnership catalyst. Monitor for patent grant and any subsequent licensing or collaboration announcements. Given the company's pre-revenue status and historical stock volatility, this event alone is unlikely to drive sustained price movement.
Key Facts
- European patent application EP 4751737 titled 'Mucoadhesive Polymers for Nasal Drug Delivery' has been published by the EPO.
- The patent covers Polyrizon's Trap & Target (T&T) mucoadhesive polymer technology platform for nasal drug delivery.
- Polyrizon is a development-stage biotech company with no revenue from product sales.
- The patent application remains in examination; grant is not assured.
- No financial terms, partnership agreements, or commercialization timelines were disclosed.
Financial Impact
No financial impact disclosed; pre-revenue development-stage company.
Risk Factors
- Patent may not be granted or may issue in a narrower form than applied for.
- Company has no revenue and limited cash runway (per 20-F, 1,608,266 shares outstanding as of Dec 31, 2025).
- Forward-looking statements about market growth and partnering are aspirational with no concrete agreements.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-067307 |
| Document: ea029428901ex99-1.htm | 0001213900-26-067307 |
| Document: 0001213900-26-067307-index-headers.html | 0001213900-26-067307 |
| Document: 0001213900-26-067307-index.html | 0001213900-26-067307 |
| Document: 0001213900-26-067307.txt | 0001213900-26-067307 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 17, 2026
1d ago
|
6-K
| $13.22 awaiting T+1 | awaiting T+1 | — | $13.23 (+0.08%) |
|
Jun 17, 2026
1d ago
|
Press Release
| $13.23 $13.42 | ▲ +1.44% | ▲ +0.66% | $13.23 (−0.00%) |
|
Jun 15, 2026
3d ago
|
6-K
| $11.45 $13.23 | ▲ +15.55% | ▲ +16.79% | $13.23 (+15.55%) |
|
Jun 15, 2026
3d ago
|
Press Release
| $10.83 $11.45 | ▲ +5.72% | ▲ +6.32% | $13.23 (+22.16%) |
|
Jun 10, 2026
8d ago
|
6-K
| $11.58 $11.13 | ▼ −3.89% | ▼ −4.43% | $13.23 (+14.25%) |
|
Jun 8, 2026
10d ago
|
6-K
| $11.45 $11.06 | ▼ −3.41% | ▼ −1.83% | $13.23 (+15.55%) |
|
Jun 8, 2026
10d ago
|
Press Release
| $12.52 $11.45 | ▼ −8.55% | ▼ −8.25% | $13.23 (+5.67%) |
|
Jun 5, 2026
13d ago
|
6-K
| $12.52 $11.45 | ▼ −8.55% | ▼ −8.25% | $13.23 (+5.67%) |
|
May 13, 2026
5w ago
|
6-K
| $15.18 $15.02 | ▼ −1.05% | ▼ −1.83% | $13.23 (−12.85%) |
|
May 4, 2026
6w ago
|
6-K
| $15.40 $14.14 | ▼ −8.18% | ▼ −8.98% | $13.23 (−14.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access